For severe liver disease. Sold as Cysteine Hydrochloride, Elcys, Nouress. Every FDA application for this active ingredient: 3 branded and 1 generic.
As of Nov 16, 2026, FDA lists 4 applications for Cysteine Hydrochloride (sold as Cysteine Hydrochloride, Elcys, Nouress), first approved Oct 22, 1986, with 0 new uses approved and 0 published complete response letters.
| N-Acetylcysteine (NAC) in Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitis (PSC) · Brigham and Women's Hospital | Phase 2 | Not yet recruiting | Nov 16, 2026 |
| Effectiveness and Safety of Cellbooster Hair in Healthy SubjectsHair and Scalp Health · Suisselle | Not applicable | Not yet recruiting | Nov 10, 2026 |
| Effectiveness and Safety of Cellbooster Glow in Healthy SubjectsWrinkle Appearance, Skin Hydration in Healthy Volunteers · Suisselle | Not applicable | Not yet recruiting | Nov 10, 2026 |
| N-Acetylcysteine for Bipolar and Alcohol Use DisordersBipolar Disorder, Alcohol Use Disorder · Medical University of South Carolina | Phase 2 | Not yet recruiting | Nov 3, 2026 |
| FEAST and HOPE: Redox PSC Pilot StudyPrimary Sclerosing Cholangitis (PSC) · Brigham and Women's Hospital | Phase 2 | Not yet recruiting | Oct 27, 2026 |
| Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus HypersecretionBronchitis, Bronchitis, Chronic · University of North Carolina, Chapel Hill | Phase 4 | Not yet recruiting | Oct 14, 2026 |
| NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled StudyAcute Myeloid Leukemia, Adult · Peking University People's Hospital | Not applicable | Not yet recruiting | Oct 9, 2026 |
| Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver FailureAcute Liver Failure · King Edward Medical University | Not applicable | Recruiting | Aug 14, 2026 |
| Oct 22, 1986 | Cysteine HydrochlorideNDA 19523 · New formulation or manufacturer | Hospira | 0 | Discontinued |
| Apr 16, 2019 | ElcysNDA 210660 · New formulation or manufacturer | Exela Pharma | 1 | Marketed |
| Dec 13, 2019 | NouressNDA 212535 · New formulation or manufacturer | Baxter Hlthcare Corp | 0 | Marketed |
| — | Cysteine HydrochlorideANDA 214082 | Dr Reddys Labs SA | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA